Simmitinib not checked

Shanghai Runshi Pharmaceutical Technology Co., Ltd · SOMCL-15-290

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
5 in total
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
How it’s given
“A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)”In the company’s words, NCT06577376 on ClinicalTrials.gov
Tested for
Advanced Oesophageal Squamous Cell Carcinoma, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past, Advanced Solid Tumor
Main trialPhase 3
“To evaluate the overall survival of simmitinib versus investigator's choice of chemotherapy for Participants with advanced or metastatic oesophageal squamous cell carcinoma who have disease progression after first-line standard therapy.”In the company’s words, NCT06656091 on ClinicalTrials.gov
Other names
SOMCL-15-290

Other drugs for Advanced Solid Tumor

All 2440 drugs for Advanced Solid Tumor

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 30 Jan 2027 A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma
Phase 1/2Not yet recruiting 26 Aug 2026 A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Phase 1/2Not yet recruiting 30 Jan 2027 A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Phase 2Unknown 30 Jan 2026 A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
Phase 1Unknown 31 Jan 2023 A Phase I Trial of Simmitinib in Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Simmitinib

Following is part of Solo: you see every change to Simmitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in